Literature DB >> 17305326

Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics.

William Heal1, Mark J Thompson, Roger Mutter, Hannah Cope, Jenny C Louth, Beining Chen.   

Abstract

Transmissible spongiform encephalopathies (TSEs) are a family of invariably fatal neurodegenerative disorders for which no effective therapeutics are currently available. In this paper, we report on the synthesis and screening of a small library of 2,4-diphenylthiazol-5-ylamine and 2,4-diphenyloxazol-5-ylamine derivatives as potential novel prion disease therapeutics. Various synthetic strategies were investigated, including a novel phosgene-mediated cyclization of 2-N-benzoylphenylglycinonitrile, and a total of 45 compounds were synthesized. Library members were tested for both binding to prion protein (PrPC) using the surface plasmon resonance technique and for inhibition of PrPSc formation in persistently infected SMB cells. Of the compounds prepared, 15 were found to bind to human PrPC and six showed inhibition of PrPSc formation, displaying EC50s between 1.5 and 20 microM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305326     DOI: 10.1021/jm0612719

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

Review 1.  Chemistry and biology of multicomponent reactions.

Authors:  Alexander Dömling; Wei Wang; Kan Wang
Journal:  Chem Rev       Date:  2012-03-22       Impact factor: 60.622

2.  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.

Authors:  Junji Hosokawa-Muto; Yuji O Kamatari; Hironori K Nakamura; Kazuo Kuwata
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  2-Aminothiazoles as therapeutic leads for prion diseases.

Authors:  Alejandra Gallardo-Godoy; Joel Gever; Kimberly L Fife; B Michael Silber; Stanley B Prusiner; Adam R Renslo
Journal:  J Med Chem       Date:  2011-01-19       Impact factor: 7.446

4.  Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.

Authors:  Zhifu Shan; Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  Prion       Date:  2016-07-03       Impact factor: 3.931

5.  Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro.

Authors:  Huiguo Lai; G Sridhar Prasad; Radhakrishnan Padmanabhan
Journal:  Antiviral Res       Date:  2012-11-02       Impact factor: 5.970

6.  2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease.

Authors:  Zhe Li; B Michael Silber; Satish Rao; Joel R Gever; Clifford Bryant; Alejandra Gallardo-Godoy; Elena Dolghih; Kartika Widjaja; Manuel Elepano; Matthew P Jacobson; Stanley B Prusiner; Adam R Renslo
Journal:  ChemMedChem       Date:  2013-03-18       Impact factor: 3.466

7.  Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.

Authors:  Yervand Eduard Karapetyan; Gian Franco Sferrazza; Minghai Zhou; Gregory Ottenberg; Timothy Spicer; Peter Chase; Mohammad Fallahi; Peter Hodder; Charles Weissmann; Corinne Ida Lasmézas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-01       Impact factor: 11.205

8.  Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds.

Authors:  Zhe Li; Satish Rao; Joel R Gever; Kartika Widjaja; Stanley B Prusiner; B Michael Silber
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

9.  Discovery of 2-aminothiazoles as potent antiprion compounds.

Authors:  Sina Ghaemmaghami; Barnaby C H May; Adam R Renslo; Stanley B Prusiner
Journal:  J Virol       Date:  2009-12-23       Impact factor: 5.103

Review 10.  Isocyanide-based multicomponent reactions towards cyclic constrained peptidomimetics.

Authors:  Gijs Koopmanschap; Eelco Ruijter; Romano Va Orru
Journal:  Beilstein J Org Chem       Date:  2014-03-04       Impact factor: 2.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.